Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
The most effective method to Shake Hands Expertly: A Bit by bit Guide - 2Instructions to Pick the Right Dental Expert for Teeth Substitution
- 3Putin says Russian forces will seize capital of Zaporizhzhya
- 4Well informed: How to Take full advantage of Your Gadgets
- 5Clovis Unified students spend spring break traveling through China
- Vote in favor of Your Number one kind of pie
- The Delight of Perusing: Book Proposals for Each Class
- Flu is rising rapidly, driven by a new variant. Here's what to know
- RFK Jr.'s diet guidelines emphasize red meat, full-fat dairy. How healthy are they?
- Fossil analysis changes what paleontologists know about how long T. rex took to grow full size
- Munich Security Conference chief defends inviting AfD lawmakers
- Visual communication Programming for Fledglings
- Avoid Slam: Exploring the Pickup Truck Transformation
- Can a mammogram help identify heart disease?
